THE EBONI STUDY

For more information about enrolling in the EBONI Study, please call 844-884-9691 ext 0 or visit https://ebonistudyinfo.com/.  

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention

FDA-Social-Graphi_20231124-092039_1

https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention

Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude is given first as two initiation injections administered one month apart, and then every two months thereafter. Patients can either start their treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to assess how well they tolerate the drug.

Continue reading

World AIDS Day – 2020

World AIDS Day – 2020  

Our Sponsors

PERSONALIZED FOR YOU

GET STARTED BY CONNECTING WITH US TODAY

qxif-book View Resources

CALL US: 844.884.9691

STAY IN THE KNOW WITH OUR NEWSLETTER

  • Support Starts Here
  • Our Programs
  • Services
  • Our Mission
  • Resources
  • Testimonials
  • Support
  • Data Collection Tool
  • Events
  • Latest News
  • FAQ's
  • Donate
  • Contact Us

24/7 ONLINE DISCUSSION
Medical and Mental Health Support

OUR LOCATION
2193 Cascade Rd SW
Atlanta GA 30311
Office Hours:
9:00 a.m. - 5:00 p.m. - Mon - Thur
9:00 a.m. - 1:00 p.m. - Fri
CLOSED - Sat & Sun

© 2023 Heather Ivy Society. All rights reserved. Website developed by GoMe